U.S. Specialty Stores Stock News

Viatris (NasdaqGS:VTRS) is presenting pivotal Phase 3 results for its investigational low dose estrogen contraceptive weekly patch at a major scientific meeting. The U.S. FDA has accepted the New Drug Application for the patch and set a target action date in July 2026. The product is positioned within Viatris' women's health franchise and represents a potential new entrant in the contraceptive market. For investors tracking NasdaqGS:VTRS, this contraceptive patch sits within a broader...

If you are wondering whether HealthEquity at around US$82.40 is a bargain or already pricing in a lot of optimism, it helps to break the story down into what the market has been doing and what the numbers actually say about value. The share price is near US$82.40 after a 0.1% slip over the last week, a 1.2% decline over the last month, and a 9.5% decline year to date, even though the 3 year return sits at 50.5% and the 5 year return at 10.6%. Recent headlines around HealthEquity have kept...

Public Storage recently reported past first-quarter 2026 results, with revenue rising to US$1,217.74 million and net income to US$526.27 million, alongside higher earnings per share and reaffirmed full-year guidance. Management also emphasized early benefits from the PS 4.0 operational upgrade and the ongoing integration of National Storage Affiliates, which they expect to enhance efficiency and long-term earnings power. Next, we’ll examine how the reaffirmed 2026 guidance and PS 4.0...

Illumina (ILMN) opened 2026 with Q1 revenue of US$1,091 million and basic EPS of US$0.88, setting the tone for how the year is starting to shape up after its recent return to profitability. Over the past five quarters, revenue has moved within a tight band between US$1,041 million and US$1,159 million, while quarterly basic EPS has ranged from US$0.82 to US$2.18. This gives investors a clearer view of how earnings power has translated from the top line. With trailing 12 month net income back...

Without a specific news headline driving Hancock Whitney (HWC) today, the stock still draws attention from investors who are reviewing recent returns, profitability figures, and its current share price of US$67.17. See our latest analysis for Hancock Whitney. Recent trading has been relatively steady, with a 1 month share price return of 4.77% and a year to date share price return of 4.20%, set against a 1 year total shareholder return of 28.01% that builds on a 109.91% total shareholder...

Roku (ROKU) has just opened 2026 earnings season with Q1 results that build on a clear turnaround in the numbers, capped by Q4 2025 revenue of about US$1.4b and basic EPS of US$0.54. Over the past year, quarterly revenue has moved from US$1,201.0m in Q4 2024 to US$1,394.9m in Q4 2025, while basic EPS shifted from a loss of US$0.24 to a profit of US$0.54. This sets up a story in which improving profitability sits at the center of the earnings debate, with margins in focus as investors weigh...

If you are wondering whether Cognizant Technology Solutions is attractively priced right now, the key is understanding what the current share price implies about its future. The stock last closed at US$52.43, after returns of a 4.9% decline over 7 days, 14.4% decline over 30 days, 35.5% decline year to date, 31.3% decline over 1 year, 12.9% decline over 3 years, and 24.1% decline over 5 years. Recent share price moves sit against a broader backdrop of ongoing interest in large IT services...

For investors considering whether Guardant Health at around US$87.60 represents fair value or a potential opportunity, this article examines what that price may indicate about the stock. The share price is US$87.60 after a 1.5% decline over the past week and a 3.9% decline over the past month. It is still up 87.0% over the past year and 270.4% over three years, while a 35.3% decline over five years provides additional context. Recent news about Guardant Health has highlighted its role in...

IDEAYA Biosciences (IDYA) is back in focus after the FDA agreed to review its New Drug Application for darovasertib plus crizotinib in first line metastatic uveal melanoma under a Real-Time Oncology Review program. See our latest analysis for IDEAYA Biosciences. Even with the FDA review decision and recent positive Phase 2/3 data, IDEAYA Biosciences’ share price has pulled back, with a 30 day share price return of a 13.21% decline and a year to date share price return of a 16.72% decline,...

Wondering whether Sportradar Group's current share price reflects its true worth, or if the market is mispricing the story. The stock last closed at US$13.26, with returns of 0.2% over 7 days, a 20.3% decline over 30 days, and year to date and 1 year returns of 43.1% and 44.1% declines, while the 3 year return sits at 1.8%. Recent coverage has focused on Sportradar Group as a listed sports data and technology provider, with attention on how it is positioned in the wider sports betting and...

Why TriNet Group is on investors’ radar today TriNet Group (TNET) has drawn attention after a period of mixed share performance, with a strong month and past week set against weaker returns over the past 3 months and year. See our latest analysis for TriNet Group. At a share price of US$44.47, TriNet Group’s recent 24% 30 day share price return contrasts with a 27% 90 day share price decline and a 44% 1 year total shareholder return loss, suggesting fading longer term momentum despite the...

Wondering if American Electric Power Company at about US$136.91 is offering fair value or if you might be paying over the odds? This article breaks down what the current pricing could mean for you. The stock last closed at US$136.91, with returns of 1.6% over 7 days, 4.0% over 30 days, 18.2% year to date, 31.4% over 1 year, 66.4% over 3 years, and 86.7% over 5 years. This provides useful context before assessing any valuation metrics. Recent trading interest has been shaped by ongoing...

First Industrial Realty Trust expanded its board and appointed Frank E. Schmitz as an independent director. The move follows a recent activist investor campaign focused on board composition and governance. The appointment comes in a contested board setting, signaling a response to shareholder pressure. For investors watching NYSE:FR, this board change occurs at a time when the stock is trading at $62.14 and has returned 31.2% over the past year and 44.6% over the past five years. Those...

Gen Digital (NasdaqGS:GEN) has partnered with xAI to bring Grok large language models into its consumer platforms via the Gen AI Foundry. The company is launching VPN for Agents, presented as an industry first security tool tailored to autonomous AI agents. Gen Digital is also expanding Norton AI Agent Protection to address new cyber risks created by AI driven agents. Gen Digital, trading at $19.37, is adding these AI focused efforts on top of a share performance record that includes a...

Ultra Clean Holdings (NasdaqGS:UCTT) announced that Clarence Granger will step down as Chairman of the Board effective May 22, 2026. Tom Edman has been appointed to assume the Chairman role as the company adjusts its leadership at the board and executive levels. This change follows a period of executive transitions while the sector is influenced by increased AI related investment. Ultra Clean Holdings, trading at $74.61, has seen sharp share price moves recently, including a 10.1% decline...

Relay Therapeutics (RLAY) has drawn fresh attention after deciding to advance zovegalisib plus Pfizer’s atirmociclib into Phase 3 for PI3Ka-mutated, HR+/HER2- metastatic breast cancer, following early safety and response data in heavily pre-treated patients. See our latest analysis for Relay Therapeutics. The share price has been volatile around the latest zovegalisib update, with a 7 day share price return of negative 15.9%, following a 90 day share price return of 66.1% and a 1 year total...

If you are wondering whether New Jersey Resources at around US$56 is offering good value today, it helps to step back and look at what the recent price and fundamentals are really telling you. The stock has recently closed at US$56, with returns of 0.3% over 7 days, 1.8% over 30 days, 21.8% year to date, 17.6% over 1 year, 23.4% over 3 years, and 54.5% over 5 years. This gives plenty of data points to weigh up how the market currently views its prospects and risks. Recent coverage around New...

Context for Helios Technologies after recent performance Helios Technologies (HLIO) has drawn renewed investor interest after a recent period where the stock showed mixed moves, with a 2.3% decline over the past week and a 2.2% decline over the past month. See our latest analysis for Helios Technologies. Despite the recent soft patch in the share price, with a 30 day share price return of a 2.18% decline, momentum over a longer window still reflects a 22.17% year to date share price gain and...

Granite Construction (GVA) is back in focus after Q1 2026 results showed stronger than expected revenue, a higher full year revenue outlook to US$5.2b to US$5.4b, and record backlog supported by acquisitions. See our latest analysis for Granite Construction. The stronger Q1 2026 update appears to have fed into the share price, with Granite Construction’s 7 day share price return of 13.01% and 30 day return of 13.98% adding to a 1 year total shareholder return of 72.64%. This suggests momentum...

If you are wondering whether Callaway Golf at around US$15.16 is still reasonably priced after its recent run, the valuation story is the key place to focus. The stock has seen sharp moves, with a 29.4% return year to date and 121.3% over the last year, set against a 32.1% decline over three years and a 51.3% decline over five years. These swings have kept Callaway Golf on many watchlists, as investors weigh shorter term momentum of 9.7% over the last 30 days against a 1% decline over the...

In April 2026, Medpace Holdings reported first-quarter 2026 results showing sales of US$706.6 million and net income of US$123.87 million, with both basic and diluted earnings per share rising year over year, and issued full-year 2026 guidance for revenue of US$2.76–2.86 billion and GAAP net income of US$487.0–511.0 million alongside President Jesse Geiger’s planned retirement. An interesting detail for investors is that Medpace’s full-year 2026 outlook assumes a 19–20% tax rate and US$27.5...

Fidelis Insurance Holdings (NYSE:FIHL) has entered into a major share repurchase agreement that ends founding shareholder CVC Falcon Holdings Limited's ownership stake. The company has also approved amendments to its Bye Laws at its latest annual meeting, signaling changes to its governance framework. These decisions mark a meaningful shift in ownership and corporate rules that is relevant for existing and prospective shareholders. Fidelis Insurance Holdings, a specialty insurance and...

If you are wondering whether Incyte's current share price still offers value or has already priced in recent enthusiasm, the next sections will walk through what the numbers actually say. Over the past year the stock has returned 55.0%, with shorter term moves of 2.4% over 7 days, 2.8% over 30 days and a year to date return of a 4.4% decline, which can change how the market views both its growth potential and its risks. Recent coverage has focused on Incyte's position in biotech and the...

Huntsman (HUN) opened 2026 with Q1 revenue of US$1.4 billion and a basic EPS loss of US$0.30, while the trailing twelve months show revenue of US$5.7 billion and a basic EPS loss of US$1.87. Over recent quarters, revenue has ranged between US$1.4 billion and US$1.5 billion, with quarterly basic EPS losses stretching from roughly US$0.02 to US$0.92. Investors are therefore looking at a business that is still working through margin pressure rather than expanding profitability. See our full...